These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29793403)

  • 1. Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria.
    Evans MA; Millar JL; Earnest A; Frydenberg M; Davis ID; Murphy DG; Kearns PA; Evans SM
    Med J Aust; 2018 Jun; 208(10):439-443. PubMed ID: 29793403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
    Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
    Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry.
    Weerakoon M; Papa N; Lawrentschuk N; Evans S; Millar J; Frydenberg M; Bolton D; Murphy DG
    BJU Int; 2015 Apr; 115 Suppl 5():50-6. PubMed ID: 25601201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in treatment choices for localised prostate cancer diagnosed in private and public health services.
    Te Marvelde L; Milne RL; Hornby CJ; Chapman AB; Giles GG; Haines IE
    Med J Aust; 2020 Nov; 213(9):411-417. PubMed ID: 32996611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
    Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
    JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
    BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
    Washington SL; Baskin AS; Ameli N; Nguyen HG; Westphalen AC; Shinohara K; Carroll PR
    AJR Am J Roentgenol; 2020 Mar; 214(3):574-578. PubMed ID: 31913068
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Location in Upgrading and Detection after Transperineal Template-Guided Mapping Biopsy for Patients in Active Surveillance and Negative Transrectal Ultrasonography-Guided Prostate Biopsy.
    Lee CU; Sung SH; Jang CT; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
    Urol Int; 2019; 103(3):262-269. PubMed ID: 31269509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.
    Radtke JP; Kuru TH; Bonekamp D; Freitag MT; Wolf MB; Alt CD; Hatiboglu G; Boxler S; Pahernik S; Roth W; Roethke MC; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):283-91. PubMed ID: 27184812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.